Screening our FDA-Approved and Bioactive Compounds Library for Antiviral Activity against SARS-CoV‑2

Berkeley, CA, 6/15/2021

Utilizing the Drug Discovery Center library of FDA-approved and well-studied preclinical and clinical compounds to screen for antivirals against SARS-CoV-2 in human pulmonary epithelial cells, we identified 13 compounds that exhibit potent antiviral activity across multiple orthogonal assays. Hits include known antivirals, compounds with anti-inflammatory activity, and compounds targeting host pathways such as kinases and proteases critical for SARS-CoV-2 replication.

Read the full story here.